Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MIRM Stock Forecast 2025-2026
$50.47
Current Price
$2.49B
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MIRM Price Targets
+56.5%
To High Target of $79.00
+43.6%
To Median Target of $72.50
+5.0%
To Low Target of $53.00
MIRM Price Momentum
+4.3%
1 Week Change
+8.8%
1 Month Change
+40.5%
1 Year Change
+22.1%
Year-to-Date Change
-6.9%
From 52W High of $54.23
+46.4%
From 52W Low of $34.47
📊 TOP ANALYST CALLS
Did MIRM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Mirum Pharma is one of their latest high-conviction picks.
Latest MIRM Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, MIRM has a bullish consensus with a median price target of $72.50 (ranging from $53.00 to $79.00). Currently trading at $50.47, the median forecast implies a 43.6% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Michael Ulz at Morgan Stanley, suggesting a 5.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MIRM Analyst Ratings
10
Buy
0
Hold
0
Sell
MIRM Price Target Range
Low
$53.00
Average
$72.50
High
$79.00
Current: $50.47
Latest MIRM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MIRM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 19, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Assumes | $73.00 |
| May 13, 2025 | Raymond James | Steven Seedhouse | Strong Buy | Maintains | $77.00 |
| May 9, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $76.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $72.00 |
| Feb 27, 2025 | Baird | Brian Skorney | Outperform | Maintains | $55.00 |
| Feb 24, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $74.00 |
| Nov 13, 2024 | Citigroup | David Lebowitz | Buy | Maintains | $68.00 |
| Nov 13, 2024 | Baird | Brian Skorney | Outperform | Maintains | $50.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $66.00 |
| Oct 17, 2024 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $49.00 |
| Oct 11, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $66.00 |
| Aug 8, 2024 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Maintains | $66.00 |
| Aug 8, 2024 | Baird | Brian Skorney | Outperform | Maintains | $44.00 |
| Aug 8, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Maintains | $60.00 |
| Jul 26, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $66.00 |
| Jul 8, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $66.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $66.00 |
| Jun 20, 2024 | Stifel | Dae Gon Ha | Buy | Maintains | $66.00 |
| Jun 18, 2024 | Citigroup | David Lebowitz | Buy | Maintains | $64.00 |
| Jun 18, 2024 | JP Morgan | Jessica Fye | Overweight | Maintains | $39.00 |
Mirum Pharmaceuticals Inc. (MIRM) Competitors
The following stocks are similar to Mirum Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mirum Pharmaceuticals Inc. (MIRM) Financial Data
Mirum Pharmaceuticals Inc. has a market capitalization of $2.49B with a P/E ratio of -27.3x. The company generates $379.25M in trailing twelve-month revenue with a -20.4% profit margin.
Revenue growth is +61.2% quarter-over-quarter, while maintaining an operating margin of -13.6% and return on equity of -33.1%.
Valuation Metrics
Market Cap
$2.49B
Enterprise Value
$2.56B
P/E Ratio
-27.3x
PEG Ratio
-57.8x
Price/Sales
6.6x
Growth & Margins
Revenue Growth (YoY)
+61.2%
Gross Margin
+79.4%
Operating Margin
-13.6%
Net Margin
-20.4%
EPS Growth
+61.2%
Financial Health
Cash/Price Ratio
+11.1%
Current Ratio
3.2x
Debt/Equity
136.0x
ROE
-33.1%
ROA
-7.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Mirum Pharmaceuticals Inc. (MIRM) Business Model
About Mirum Pharmaceuticals Inc.
What They Do
Develops therapies for rare liver diseases.
Business Model
The company focuses on developing and commercializing innovative therapies specifically targeting rare diseases, with a primary emphasis on liver conditions. Mirum Pharmaceuticals generates revenue through the successful development and regulatory approval of its therapies, which are then marketed to healthcare providers and patients in need of specialized treatments.
Additional Information
Mirum is particularly noted for its work on Alagille syndrome, a rare genetic disorder, and aims to address significant unmet medical needs in this area. The company is committed to advancing research, facilitating regulatory approvals, and ensuring global access to its therapies, thereby playing a crucial role in the healthcare sector and improving patient quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
334
CEO
Mr. Christopher Peetz
Country
United States
IPO Year
2019
Website
www.mirumpharma.comMirum Pharmaceuticals Inc. (MIRM) Latest News & Analysis
Latest News
Quick Summary
Mirum Pharmaceuticals' stock has risen 236% since its 2019 IPO and is currently approaching a buy point following recent earnings.
Why It Matters
Mirum Pharmaceuticals' 236% stock increase shows strong market interest and potential growth, making it an attractive opportunity near a buy point after earnings.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Mirum Pharmaceuticals announced inducement grants under Nasdaq Listing Rule 5635(c)(4) in Foster City, California.
Why It Matters
Mirum Pharmaceuticals' inducement grants may signal confidence in attracting talent, potentially enhancing future growth and stability, impacting stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. Investors should monitor upcoming developments for potential impacts on stock performance.
Why It Matters
Mirum Pharmaceuticals' earnings report may signal growth potential or challenges ahead, directly influencing stock performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Mirum Pharmaceuticals has appointed Doug Sheehy, JD, as Chief Legal Officer, signaling a leadership change within the company.
Why It Matters
Leadership changes can impact company strategy and operations, potentially influencing stock performance and investor confidence in Mirum Pharmaceuticals.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Mirum Pharmaceuticals (Nasdaq: MIRM) will participate in the H.C. Wainwright BioConnect Conference on May 20, 2025, and the RBC Capital Markets Global Healthcare Conference.
Why It Matters
Mirum Pharmaceuticals' participation in key investor conferences signals engagement with the investment community, potentially attracting interest and driving stock activity around its rare disease therapies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
MIRM reported stronger-than-expected Q1 2025 results and has increased its revenue guidance for the year.
Why It Matters
MIRM's strong Q1 results and raised revenue guidance indicate growth potential, likely boosting investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About MIRM Stock
What is Mirum Pharmaceuticals Inc.'s (MIRM) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Mirum Pharmaceuticals Inc. (MIRM) has a median price target of $72.50. The highest price target is $79.00 and the lowest is $53.00.
Is MIRM stock a good investment in 2026?
According to current analyst ratings, MIRM has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $50.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MIRM stock?
Wall Street analysts predict MIRM stock could reach $72.50 in the next 12 months. This represents a 43.6% increase from the current price of $50.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mirum Pharmaceuticals Inc.'s business model?
The company focuses on developing and commercializing innovative therapies specifically targeting rare diseases, with a primary emphasis on liver conditions. Mirum Pharmaceuticals generates revenue through the successful development and regulatory approval of its therapies, which are then marketed to healthcare providers and patients in need of specialized treatments.
What is the highest forecasted price for MIRM Mirum Pharmaceuticals Inc.?
The highest price target for MIRM is $79.00 from at , which represents a 56.5% increase from the current price of $50.47.
What is the lowest forecasted price for MIRM Mirum Pharmaceuticals Inc.?
The lowest price target for MIRM is $53.00 from Michael Ulz at Morgan Stanley, which represents a 5.0% increase from the current price of $50.47.
What is the overall MIRM consensus from analysts for Mirum Pharmaceuticals Inc.?
The overall analyst consensus for MIRM is bullish. Out of 16 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $72.50.
How accurate are MIRM stock price projections?
Stock price projections, including those for Mirum Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 9:44 AM UTC